Table 2.
Somatic mutations in AR-associated NCoA and NCoR coregulators in clinical PCa. COSMIC and cBio databases were queried for somatic mutations in genes that encode AR-associated NCoAs and NCoRs (28). The COSMIC database was queried via the Cancer browser, selecting for “prostate cancer” and “carcinoma” histology, and retrieving only data from genome-wide sequencing efforts. For cBIO analysis, datasets analyses are marked by first author of study that was examined.
| Genes | COSMIC |
cBIO |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # | ADT-naïve | ADT-naïve | ADT-naïve | ADT-naïve | ADT-naïve | + CRPC | CRPC | CRPC | ADT-naïve | CRPC | ||||||
| n=1 976 | Barbieri | n=112 | Fraser | n=477 | TCGA | n=333 | Armenia | n=1 013 | Abida | n=444 | Beltran | n=114 | n=922 | n=558 | ||
| % | # | % | # | % | # | % | # | % | # | % | # | % | average% | average% | ||
| NCOA1 | 10 | 0.51 | 0 | 0.00 | 0 | 0.00 | 2 | 0.60 | 6 | 0.59 | 2 | 0.45 | 0 | 0.00 | 0.20 | 0.23 |
| NCOA2 | 9 | 0.46 | 2 | 1.79 | 1 | 0.21 | 1 | 0.30 | 8 | 0.79 | 4 | 0.90 | 0 | 0.00 | 0.77 | 0.45 |
| NCOA3 | 11 | 0.56 | 1 | 0.89 | 3 | 0.63 | 2 | 0.60 | 6 | 0.59 | 2 | 0.45 | 1 | 0.88 | 0.71 | 0.66 |
| NCOA4 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.60 | 3 | 0.30 | 1 | 0.23 | 0 | 0.00 | 0.20 | 0.11 |
| NCOA6 | 17 | 0.86 | 1 | 0.89 | 1 | 0.21 | 2 | 0.60 | 10 | 0.99 | 4 | 0.90 | 0 | 0.00 | 0.57 | 0.45 |
| NCOR1 | 19 | 0.96 | 2 | 1.79 | 4 | 0.84 | 6 | 1.80 | 26 | 2.57 | 13 | 2.93 | 2 | 1.75 | 1.48 | 2.34 |
| NCOR2 | 28 | 1.42 | 1 | 0.89 | 1 | 0.21 | 0 | 0.00 | 23 | 2.27 | 14 | 3.15 | 1 | 0.88 | 0.37 | 2.02 |
Corresponding cBIO annotations is as follows: Barbieri, Prostate Adenocarcinoma (Broad/Cornell, Nature Genetics 2012); Fraser, Prostate Adenocarcinoma (CPC-Gene, Nature 2017); Armenia, Prostate Adenocarcinoma (MSKCC/DFCI, Nature Genetics 2018); Abida, Metastatic Prostate Adenocarcimoma, SU2C/PCF Dream Team, PNAS 2019; Beltran, Neuroendocrine Prostate Cancer (Multi-institute, Nature Medicine 2016). Note that the study of Armenia et al. includes data from 680 ADT-naïve and 333 CRPC cases; data from this study have not been taken into consideration in determining average %.
#, number of somatic mutations/study that affects the gene for which the symbol is listed.
%, percentage of cases/study that harbor somatic mutation that affects the gene for which the symbol is listed.
Average %, average of percentage of mutations from studies on either ADT-naïve PCa or CRPC specimens; ADT, androgen deprivation therapy; CRPC, castration-resistant PCa; PCa, prostate cancer.